{"schema_version":"secwatch.filing_event.v1","accession":"0001387131-23-007787","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2023-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.842437+00:00","generated_at":"2026-06-13T17:00:10.887038+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tonix Pharma acquires two FDA-approved migraine products Zembrace SymTouch and Tosymra for $25M cash plus earn-outs","bullets":["Upfront $12M at closing, $3M in Mar 2024, ~$10M for inventory; earn-out royalties based on net sales tiers.","Acquired products generated ~$23M in 2022 sales (Zembrace $19.6M, Tosymra $3.5M); patent protection to 2036/2031.","Closing expected June 30, 2023; Upsher-Smith provides transition services for up to 9 months post-close.","Deal builds commercial infrastructure ahead of potential TNX-102 SL fibromyalgia launch; aligns with TNX-1900 chronic migraine program.","Managed care contracts covering ~200M patients; products bypass GI tract, useful for migraine with nausea."],"urls":{"canonical":"https://secwatch.observer/filing/0001387131-23-007787","json":"https://secwatch.observer/filing/0001387131-23-007787.json","markdown":"https://secwatch.observer/filing/0001387131-23-007787.md","text":"https://secwatch.observer/filing/0001387131-23-007787.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123007787/0001387131-23-007787-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123007787/tnxp_8k-062323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T17:00:10.887038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d55a20ccede80f7bd2605e5e6b9b440bd724a4af","claim":"Tonix Pharmaceuticals Holding Corp. entered into Asset Purchase Agreement with Upsher Smith Laboratories, LLC valued at $15 million in cash (Cash Purchase Price) (effective 2023-06-23).","evidence_excerpt":"On June 23, 2023, Tonix Pharmaceuticals Holding Corp, Inc. (the “ Company ”) and its wholly owned subsidiary Tonix Medicines, Inc., a Delaware corporation (“ Acquisition Sub ” and together with the Company, “ Purchaser ”), entered into that certain Asset Purchase Agreement (the “ Asset Purchase Agreement ”) with Upsher Smith Laboratories, LLC, a Minnesota limited liability company (“ Seller ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123007787/0001387131-23-007787-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Upsher Smith Laboratories, LLC"},{"label":"Value","value":"$15 million in cash (Cash Purchase Price)"},{"label":"Effective","value":"2023-06-23"}],"fact_type":"material_agreement"},{"claim_id":"efa020d16c07080bbfe758d084bc8333c27b7d5f","claim":"Tonix Pharmaceuticals Holding Corp. entered into Transition Services Agreement with Upsher Smith Laboratories, LLC valued at base fees equal to $100,000 per month for the first six months, and $150,000 per months for the seve.","evidence_excerpt":"In connection with the Asset Purchase and of as the Closing date, Purchaser will enter into a Transition Services Agreement (the “ Transition Services Agreement ”) with Seller.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123007787/0001387131-23-007787-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Upsher Smith Laboratories, LLC"},{"label":"Value","value":"base fees equal to $100,000 per month for the first six months, and $150,000 per months for the seve"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}